State of Wyoming Has $546,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

State of Wyoming boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 103.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,431 shares of the specialty pharmaceutical company’s stock after buying an additional 2,251 shares during the period. State of Wyoming’s holdings in Jazz Pharmaceuticals were worth $546,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of JAZZ. Fuller & Thaler Asset Management Inc. raised its position in Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at $59,668,000. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after buying an additional 320,724 shares during the period. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after buying an additional 315,608 shares during the period. Finally, GMT Capital Corp raised its position in Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after buying an additional 296,800 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the purchase, the director now directly owns 100,000 shares in the company, valued at $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. The trade was a 1.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JAZZ. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Barclays reaffirmed an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $108.98 on Monday. The company has a market cap of $6.72 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The stock has a 50-day moving average of $115.73 and a 200-day moving average of $122.09. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business’s revenue was down .5% compared to the same quarter last year. During the same quarter last year, the company posted $2.68 EPS. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.